Abivax Reports Q1 Results with Strong Cash Position
Abivax reported cash, cash equivalents, and short-term investments totaling €491.6 million as of March 31, 2026, projecting a cash runway into Q4 2027 based on current operating assumptions.
Tickers: $ABVX
Topics: biotech capital_structure